WBB Securities Acts as Financial Advisor to T2 Biosystems for $50 Million Credit Facility

For Immediate Release
January 5, 2017

PDF:  WBB Securities Acts as Financial Advisor to T2 Biosystems for $50 Million Credit Facility

SAN DIEGO, CA – WBB Securities acted as financial advisor to T2 Biosystems, Inc., a manufacturer of next generation diagnostic equipment, for a credit facility up to $50 million. T2 Biosystems currently sells its systems to hospitals across the nation. The credit facility was offered by CRG LP, a premier healthcare investment group. T2 Biosystems will have immediate access to $40 million through the facility and will utilize $28 million of the proceeds to retire existing debt. Another $10 million will be made available to T2 Biosystems by the lenders upon achievement of certain operational milestones.

T2 Biosystems intends to use the net proceeds from the offering principally for general corporate purposes, working capital and the company’s strategic priorities.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.

The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $4 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain. For more information, please visit www.wbbsec.com.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.